Institute Pasteur Korea

Seoul, South Korea

Institute Pasteur Korea

Seoul, South Korea

Time filter

Source Type

Patent
Institute Pasteur Korea | Date: 2015-04-17

The present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis C virus (HCV).


Patent
Institute Pasteur Korea | Date: 2015-06-22

The present invention relates to small molecule compounds having the general formula (I): wherein A is a moiety selected from the group consisting of formulae (A) to (K) and their use in the treatment of bacterial infections, in particular Tuberculosis.


Patent
Institute Pasteur Korea | Date: 2017-04-26

The present invention relates to small molecule compounds having the general formula (I): wherein A is a moiety selected from the group consisting of formulae (A) to (K) and their use in the treatment of bacterial infections, in particular Tuberculosis.


The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X^(1 )and X^(2 )are independently, at each occurrence, CR^(5 )or N; Y is C_(1)-C_(6 )alkylene, wherein alkylene is optionally substituted with one to two C_(1)-C_(3 )alkyl groups; R^(1 )is selected from the group consisting of hydrogen, halogen, C_(1)-C_(6 )alkoxy, NH_(2), NHR^(6), NR^(7)R^(8 )and NH(R^(9))_(n)R^(10), n being 0 or 1; R^(2 )is selected from the group consisting of hydrogen, halogen, C_(1)-C_(6 )alkyl, NH_(2), NHR^(6), NR^(7)R^(8 )and NH(R^(9))_(n)R^(10); R^(3 )is selected from the group consisting of hydrogen, hydroxyl, OR^(11), NR^(7)R^(8), C_(1)-C_(6 )alkoxy, C_(1)-C_(6 )alkyl, C_(3)- C_(10 )cycloalkyl, C_(1)-C_(3 )haloalkyl, C(O)NHR^(11), aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^(a )groups; and R^(4 )is selected from the group consisting of NH_(2), N(R^(12))(V)_(p)R^(13), NH(V)_(p)OR^(14), NHC(O)R^(15), and groups of formula 1a shown below, and their use in the treatment of diseases, in particular inflammatory diseases, cancer, stroke and/or Alzheimers disease.


The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X1 and X2 are independently, at each occurrence, CR5 or N; Y is C1-C6 alkylene, wherein alkylene is optionally substituted with one to two C1-C3 alkyl groups; R1 is selected from the group consisting of hydrogen, halogen, C1-C6 alkoxy, -NH2, -NHR6, -NR7R8 and -NH-(R9)n-R10, n being 0 or 1; R2 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, -NH2, -NHR6, - NR7R8 and -NH-(R9)n-R10; R3 is selected from the group consisting of hydrogen, hydroxyl, OR11, -NR7R8, C1-C6 alkoxy, C1-C6 alkyl, C3-C10 cycloalkyl, C1-C3 haloalkyl, -C(O)NHR11, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Ra groups; and R4 is selected from the group consisting of -NH2, -N(R12)(V)pR13, - NH(V)p-OR14, -NHC(O)R15, and groups of formula la shown below, and their use in the treatment of diseases, in particular inflammatory diseases, cancer, stroke and/or Alzheimers disease.


Patent
Institute Pasteur Korea | Date: 2017-02-22

The present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis C virus (HCV).


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2010.2.3.2-2 | Award Amount: 8.47M | Year: 2011

Early stage Drug Discovery efforts over the last 5 years have resulted in the identification of a number of promising lead compounds in the fight against TB. These leads need to be further progressed and optimised into candidates for pre-clinical development through the Drug Development progression cascade. Three compound families are of particular interest: 1) InhA Inhibitors, 2) New potent whole cell anti-tubercular compounds with unknown mode of action and 3) new Beta-lactam/Beta-lactamase combinations for TB. A preclinical package is already in place for some of them, but further work is necessary for others in order to justify the progression of a single anti-tubercular family to the more resource intensive stages of preclinical and clinical development. The project will encompass the parallel progression of the three compound families through: A) Lead Optimization Chemistry efforts and MoA studies (Genetic and Proteomic) for whole cell inhibitors, B) In vitro and in vivo evaluation of a new orally bioavailable Beta-lactam alone or in combination with a Beta-lactamase inhibitor to evaluate the sterilising potential of the new drug/s and C) the optimization of an InhA inhibitor for later preclinical development. These efforts will yield candidate molecules for new information rich in vitro assays of antimycobacterial activity (artificial granuloma, activity against slow/non growing cells and activity against clinical isolates) as well as for in vivo safety and efficacy evaluation in different animal models of infection (acute and/or chronic). At this stage a single compound family will be prioritized. Further studies will be performed assessing the potential for shortening treatment in stand alone therapy as well as in combination regimens both in vitro and in vivo. Finally a Clinical Development plan will be put in place for the selected candidate molecule.


Patent
Institute Pasteur Korea | Date: 2014-05-14

The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.


Patent
Institute Pasteur Korea, French Institute of Health and Medical Research | Date: 2014-04-28

The present invention relates to 4H-pyrido[1,2-a]pyrimidin-4-one compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.


Patent
Institute Pasteur Korea and Qurient Co. | Date: 2014-08-01

The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.

Loading Institute Pasteur Korea collaborators
Loading Institute Pasteur Korea collaborators